Compare

Sandoz Group AG/Fr. SDZ

1D1W1MYTD1Y5YMAX

About Sandoz Group AG

Sandoz Group AG operates in the pharmaceutical industry and is primarily focused on the development, production, and marketing of generic pharmaceuticals and biosimilars. The company offers a wide range of products including antibiotics, dermatology treatments, and respiratory medicines. Sandoz initially began as an independent company and has a notable history as part of the larger Novartis group, from which it separated to re-establish its standalone position. Headquartered in Basel, Switzerland, Sandoz has a significant global presence in various key markets. The company's strategic positioning is bolstered by its extensive portfolio of generic and biosimilar medicines, allowing it to compete effectively within the cost-sensitive segments of the pharmaceutical market.
Ticker
Fr. SDZ
Sector
Health
Primary listing
XSWX
Employees
20,000
Headquarters
Basel, Switzerland
Website
www.sandoz.com

Sandoz Group AG Metrics

BasicAdvanced
CHF 30B
56.36
CHF 1.22
0.49
CHF 0.80
1.17%

What the Analysts think about Sandoz Group AG

Analyst ratings (Buy, Hold, Sell) for Sandoz Group AG stock.
Analyst projections of the future price of Sandoz Group AG stock.

Bulls say / Bears say

Second-quarter net sales rose 9%, with biosimilar sales up 22% at constant currencies. The strong performance shows Sandoz is converting recent product launches into current growth. (Reuters)
A wave of patent expiries gives Sandoz room to expand its biosimilar business, which it aims to grow to more than 100 products by 2040. The company targets more than doubling sales between 2025 and 2035. (Reuters)
A Henlius partnership gives Sandoz rights outside China to commercialise up to 10 biosimilar candidates. This could broaden its future launch pipeline by drawing on a partner for development and manufacturing. (EQS News)
The US has threatened tariffs of 100% on imported generics from 2028, rising to 200% the following year. Sandoz said it plans to close its only US manufacturing site by the end of 2026, leaving a potential cost and supply risk if the tariffs take effect. (Reuters)
Sandoz now expects overall pricing to fall by a mid-single-digit percentage in 2026, a steeper decline than its earlier forecast. Pressure in Germany and North America could offset some of the benefit from sales growth and a richer biosimilar mix. (Sandoz)
Sandoz agreed to pay $450 million to settle US state claims over alleged generic-drug price-fixing, with payments spread over seven years. Individual plaintiffs who opted out of settlements still have claims outstanding. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2026.

Sandoz Group AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Sandoz Group AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Sandoz Group AG

AllEURGBPUSD
Funds
Fund name
Fund size
Fr. SDZ weighting
iShares STOXX Europe 600 Health Care€EXV4
€687M2.03%
iShares MSCI Europe Health Care Sector€ESIH
€863M2.03%
iShares MSCI Europe Health Care Sector£ESIH
£741M2.03%
iShares MSCI Europe ex-UK€IEUX
€1.5B0.33%
iShares MSCI Europe ex-UK£IEUX
£1.3B0.33%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.